Agreements

Date: 2017-02-21

Type of information: Development agreement

Compound: IFN alpha Kinoid

Company: Neovacs (France) BioSense Global (USA - NJ)

Therapeutic area: Autoimmune diseases - Dermatological diseases - Inflammatory diseases

Type agreement: development - commercialisation

Action mechanism: kinoid/immunotherapy product. A Kinoid is obtained by chemically linking the cytokine of interest to a foreign carrier protein, KLH ( Keyhole Limpet Hemocyanin), and then treating the resultant compound to inactivate the cytokine. These active immunotherapies have been designed to induce an antibody response (self-polyclonal antibodies) by the patient’s immune system that targets a particular over-expressed cytokine responsible for the pathogenesis and development of a given disease. The Kinoid technology can be applied in principle to any cytokine target.

Disease: lupus, dermatomyositis

Details:

• • On February 21, 2017, Neovacs announced that it has signed with BioSense Global a commercial license option agreement for its IFN? Kinoid vaccine to treat lupus and dermatomyositis in China. China is the world’s second largest pharmaceutical market, where close to 1 million patients are suffering from lupus. BioSense will conduct the necessary pivotal clinical trial and achieve regulatory approvals of IFN alpha Kinoid in China and other selected territories. Upon successful completion of Neovacs’ ongoing phase IIb trial for IFN alpha kinoid in lupus (SLE), BioSense will receive commercial rights for IFN alpha Kinoid in both indications lupus and dermatomysitis.

Financial terms: The transaction is worth up to €65 million in upfront and milestone payments, not including double-digit sales royalties.

Latest news:

Is general: Yes